Authorized purpose: Adult thyroid ultrasound reporting aid for localizing and characterizing suspicious nodules with ACR TI-RADS descriptors and categories.
Clinical role
Stand-alone lesion localization, characterization, and structured-reporting aid; the clinician may modify the report during quality control and patient management must not rely solely on the software analysis.
Images and patients
Ultrasound · Thyroid
Key limitation
Keep in mind: The report requires qualified-clinician review, quality control, and approval; the software is not an independent source of medical advice and patient-management decisions must not be based solely on its analysis. Exact current interfaces, versions, and local compatibility are not established.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Adult thyroid ultrasound reporting aid for localizing and characterizing suspicious nodules with ACR TI-RADS descriptors and categories.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Thyroid Input: DICOM thyroid ultrasound images from DICOM-compliant ultrasound imaging devices for adults aged 22 years or older referred for examination.
Who uses it?Intended users: Trained medical professionals, including physicians and medical technicians such as radiologists; a qualified clinician reviews and approves the report.
What does the software produce?Output: Regions of interest placed on thyroid ultrasound images, ACR TI-RADS lexicon descriptors for composition, echogenicity, shape, margin, and echogenic foci, a calculated TR-1 through TR-5 category, and a structured report with measurement and annotation tools.
What is its most important limitation?Key limitation: The report requires qualified-clinician review, quality control, and approval; the software is not an independent source of medical advice and patient-management decisions must not be based solely on its analysis. Exact current interfaces, versions, and local compatibility are not established.
Clinical takeaway. Clinical role: Adult thyroid ultrasound reporting aid for localizing and characterizing suspicious nodules with ACR TI-RADS descriptors and categories.
Evidence takeaway. Evidence from the reviewed source record: FDA performance testing included a standalone study and an MRMC reader study with 600 unique patients/cases and 18 board-certified radiologists. For localization at IoU greater than 0.5, average reader AUC was 0.758 aided, 0.736 unaided, and standalone AUC was 0.703 (95% CI 0.642-0.762). Reader localization accuracy was 95.6% aided, 93.6% unaided, and 95.1% standalone. Standalone descriptor accuracy was 86.7% composition, 68.2% echogenicity, 93.4% shape, 58.4% margin, and 70.3% echogenic foci; standalone overall TI-RADS-level agreement was 63.8% (95% CI 60.0-67.7). Ground truth used FNA or two-year follow-up for benign/malignant status and expert radiologist consensus with adjudication for localization and descriptors.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Adult thyroid ultrasound reporting aid for localizing and characterizing suspicious nodules with ACR TI-RADS descriptors and categories.
Stand-alone lesion localization, characterization, and structured-reporting aid; the clinician may modify the report during quality control and patient management must not rely solely on the software analysis.
Regions of interest placed on thyroid ultrasound images, ACR TI-RADS lexicon descriptors for composition, echogenicity, shape, margin, and echogenic foci, a calculated TR-1 through TR-5 category, and a structured report with measurement and annotation tools.
Trained medical professionals, including physicians and medical technicians such as radiologists; a qualified clinician reviews and approves the report.
The report requires qualified-clinician review, quality control, and approval; the software is not an independent source of medical advice and patient-management decisions must not be based solely on its analysis. Exact current interfaces, versions, and local compatibility are not established.
FDA performance testing included a standalone study and an MRMC reader study with 600 unique patients/cases and 18 board-certified radiologists. For localization at IoU greater than 0.5, average reader AUC was 0.758 aided, 0.736 unaided, and standalone AUC was 0.703 (95% CI 0.642-0.762). Reader localization accuracy was 95.6% aided, 93.6% unaided, and 95.1% standalone. Standalone descriptor accuracy was 86.7% composition, 68.2% echogenicity, 93.4% shape, 58.4% margin, and 70.3% echogenic foci; standalone overall TI-RADS-level agreement was 63.8% (95% CI 60.0-67.7). Ground truth used FNA or two-year follow-up for benign/malignant status and expert radiologist consensus with adjudication for localization and descriptors.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA performance testing included a standalone study and an MRMC reader study with 600 unique patients/cases and 18 board-certified radiologists. For localization at IoU greater than 0.5, average reader AUC was 0.758 aided, 0.736 unaided, and standalone AUC was 0.703 (95% CI 0.642-0.762). Reader localization accuracy was 95.6% aided, 93.6% unaided, and 95.1% standalone. Standalone descriptor accuracy was 86.7% composition, 68.2% echogenicity, 93.4% shape, 58.4% margin, and 70.3% echogenic foci; standalone overall TI-RADS-level agreement was 63.8% (95% CI 60.0-67.7). Ground truth used FNA or two-year follow-up for benign/malignant status and expert radiologist consensus with adjudication for localization and descriptors.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
See-Mode Augmented Reporting Tool, Thyroid (SMART-T) regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K240697
Samplen=600
IndependenceIndependence not established
K240697
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240697. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM thyroid ultrasound images from DICOM-compliant ultrasound imaging devices for adults aged 22 years or older referred for examination.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Web-based client-server software accessed through a browser on a standard off-the-shelf computer, with DICOM input from ultrasound devices and structured-report output; the FDA packet does not establish a specific PACS, RIS, EHR, or interface version.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-08 ·
Returned objects
Source context, not route validation: Regions of interest placed on thyroid ultrasound images, ACR TI-RADS lexicon descriptors for composition, echogenicity, shape, margin, and echogenic foci, a calculated TR-1 through TR-5 category, and a structured report with measurement and annotation tools.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Regions of interest placed on thyroid ultrasound images, ACR TI-RADS lexicon descriptors for composition, echogenicity, shape, margin, and echogenic foci, a calculated TR-1 through TR-5 category, and a structured report with measurement and annotation tools.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Web-based client-server software accessed through a browser on a standard off-the-shelf computer, with DICOM input from ultrasound devices and structured-report output; the FDA packet does not establish a specific PACS, RIS, EHR, or interface version.
ACR AI Central provides an exact-submission model card for See-Mode Augmented Reporting Tool, Thyroid (SMART-T); FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K240697 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-08 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: PIUR tUS Infinity supports a computer-aided thyroid ultrasound workflow that identifies thyroid lobes and margins, calculates volume, marks and quantifies nodules, and provides user-selected ACR TI-RADS parameters subject to user review and confirmation.
Authorized purpose: Views and quantifies thyroid ultrasound data with machine learning to aid thyroid-lobe analysis and identify, quantify, and document nodules in adults age 18 or older.
Authorized purpose: Alturion Series diagnostic ultrasound systems acquire and display ultrasound images and fluid-flow information for the labeled fetal, abdominal, cardiac, cephalic, obstetric, musculoskeletal, ophthalmic, urologic, vascular, small-organ, and lung examinations.
Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; ophthalmic; urologic organs; and lung
Authorized purpose: Supervised automatic ultrasound image acquisition of hand and wrist joints in adults being investigated or monitored for musculoskeletal disease.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.